Abstract

Eosinophilic Esophagitis: Treatment with Oral Viscous Budesonide

Author(s): Zur Eyal

Issue: Jul/Aug 2012 - Volume 16, Number 4

Page(s): 288-293

Download in electronic PDF format for $75
  • Eosinophilic Esophagitis: Treatment with Oral Viscous Budesonide Page 1
  • Eosinophilic Esophagitis: Treatment with Oral Viscous Budesonide Page 2
  • Eosinophilic Esophagitis: Treatment with Oral Viscous Budesonide Page 3
  • Eosinophilic Esophagitis: Treatment with Oral Viscous Budesonide Page 4
  • Eosinophilic Esophagitis: Treatment with Oral Viscous Budesonide Page 5
  • Eosinophilic Esophagitis: Treatment with Oral Viscous Budesonide Page 6

Abstract

Eosinophilic esophagitis is a clinicopathologic disease isolated to the esophagus. It is caused by immunologic reactions to ingested and inhaled allergans. Symptoms include regurgitation, vomiting, pain, anorexia, and dysphagia. Endoscopy with biopsy is currently the only reliable diagnostic test for eosinophilic esophagitis. The disease should remit with treatments of dietary exclusion, topical corticosteroids, or both. Oral viscous budesonide is one of the promising options of topical corticosteroid to treat eosinophilic esophagitis. Since there are no commercial medicines of oral viscous budesonide, it is solely a compounded medication. This article briefly discusses the properties of the disease and covers a few compounding possibilities to oral viscous budesonide.

Related Keywords

  • eosinophilic esophagitis
  • esophagus
  • immunologic reaction
  • allergens
  • dietary restrictions
  • topical administration
  • oral gel
  • viscous budesonide
  • topical corticosteroid
  • steroid gel
  • formulation

Related Categories

  • EAR NOSE THROAT
  • FORMULATIONS
  • ALLERGY/IMMUNOLOGY/INFLAMMATION

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Jul/Aug 2012
Pg. 288-293
Eosinophilic Esophagitis: Treatment with Oral Viscous Budesonide
Author(s): Zur Eyal
Jul/Aug 2004
Pg. 269-274
Current Topical Treatments in Wound Healing - Part 1
Author(s): Helmke Christopher D
Jul/Aug 2021
Pg. 323
Budesonide 0.0.25% Mucoadhesive Gel
Author(s): Allen Loyd V Jr
Sep/Oct 2019
Pg. 376-381
Oral Viscous Sucralfate Gel for Post-procedural Treatment of Barrett's Esophagus
Author(s): Zur Eyal
Jul/Aug 2017
Pg. 322-329
Physical and Chemical Stability of Budesonide Mucoadhesive Oral Suspensions (MucoLox)
Author(s): Ip Kendice, Carvalho Maria, Shan Ashley, Banov Daniel
May/Jun 2015
Pg. 243
Lidocaine Hydrochloride 2% Viscous Oral Topical Solution
Author(s): Allen Loyd V Jr
May/Jun 2004
Pg. 206-209
Basics of Compounding for Cold Sores or Fever Blisters
Author(s): Allen Loyd V Jr
Jul/Aug 2003
Pg. 266-270
Sensitization Therapy for Warts
Author(s): Kuntz Rachael
Sep/Oct 2015
Pg. 357-365
Novel Approaches to Topical Psoriasis Therapy
Author(s): Koyama Gregory, Liu Jenny, Scaffidi Alyse, Khazraee Maryam, Epstein Benjamin
Jul/Aug 2018
Pg. 317
Budesonide 1-mg//10-mL Mucolox Oral Suspensions
Author(s): Allen Loyd V Jr
May/Jun 2003
Pg. 176-178
Case Report: Topical Gel for the Treatment of a Refractory Leg Ulcer
Author(s): Israel Alan
Jul/Aug 2003
Pg. 288-291
Basics of Compounding for Raynaud's Disease
Author(s): Glasnapp Andrew
Jan/Feb 2004
Pg. 10-14
Women's Oral Health: Is There a Hormonal Link?
Author(s): Preckshot John
May/Jun 2013
Pg. 254-261
Physiochemical Compatibility of Nebulizable Drug Admixtures Containing Budesonide and Colistmethate or Hypertonic Saline
Author(s): Klemmer Anja, Krämer Irene, Kamin Wolfgang
Sep/Oct 2024
Pg. 400
Lidocaine Hydrochloride 2% Viscous Oral Topical Solution
Author(s): Allen Loyd V Jr
Nov/Dec 2024
Pg. 486
Lidocaine Hydrochloride 2% Viscous Oral Topical Solution
Author(s): Allen Loyd V Jr
Nov/Dec 2012
Pg. 462-469
Recurrent Aphthous Stomatitis: Topical Treatment with Minocycline and Other Evidence-based Agents
Author(s): Zur Eyal
Nov/Dec 2022
Pg. 509
Curcumin 2% Topical Gel
Author(s): Allen Loyd V Jr
May/Jun 2018
Pg. 232
Anhydrous Silicon Base Topical Gel Vehicle
Author(s): Allen Loyd V Jr
Sep/Oct 2019
Pg. 366-375
Topical Treatment of Cutaneous Leishmaniasis in Israel, Part 3
Author(s): Zur Eyal